```mermaid
flowchart TD
Notch["Notch Receptor<br/>Pathway"]
ALS["ALS Disease"]
Cancer["Cancer"]
Inflammation["Inflammation"]
AlzheimersDisease["Alzheimer's Disease"]
NOTCH1["NOTCH1 Gene"]
SYNCRIP["SYNCRIP Gene"]
ProgenitorFate["Progenitor Cell<br/>Fate Determination"]
NeuronalDiff["Neuronal Subtype<br/>Differentiation"]
CellSurvival["Cell Survival<br/>Regulation"]
Apoptosis["Apoptosis<br/>Control"]
Neurodegeneration["Neurodegeneration<br/>Process"]
CervicalCancer["Cervical Cancer"]
TherapeuticTarget["Therapeutic<br/>Target"]
ALS -->|"activates"| Notch
ALS -->|"regulates"| Notch
Cancer -->|"regulates"| Notch
Inflammation -->|"activates"| Notch
Inflammation -->|"regulates"| Notch
AlzheimersDisease -->|"associated_with"| Notch
NOTCH1 -->|"inhibits"| Notch
SYNCRIP -->|"regulates"| Notch
Notch -->|"regulates"| ProgenitorFate
Notch -->|"involved_in"| NeuronalDiff
Notch -->|"regulates"| CellSurvival
Notch -->|"controls"| Apoptosis
Notch -->|"participates_in"| Cancer
Notch -->|"participates_in"| CervicalCancer
Notch -->|"contributes_to"| Neurodegeneration
Notch -->|"potential_target"| TherapeuticTarget
style Notch fill:#006494
style NOTCH1 fill:#4a1a6b
style SYNCRIP fill:#4a1a6b
style ProgenitorFate fill:#1b5e20
style NeuronalDiff fill:#1b5e20
style CellSurvival fill:#1b5e20
style ALS fill:#ef5350
style Cancer fill:#ef5350
style In
title: Notch2 Protein
category: protein
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Notch2 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Notch2</td></tr>
<tr><td><strong>Gene</strong></td><td>[NOTCH2](/genes/notch2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q12983](https://www.uniprot.org/uniprot/Q12983)</td></tr>
<tr><td><strong>PDB Structure</strong></td><td>5MNW, 3LJP</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~265 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Notch receptor family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">139 edges</a></td>
</tr>
</table>
</div>
Notch2 is a single-pass transmembrane receptor that serves as a critical component of the evolutionarily conserved Notch signaling pathway. As one of four mammalian Notch receptors (NOTCH1-4), Notch2 plays essential roles in neural development, synaptic plasticity, cerebrovascular homeostasis, and tissue maintenance throughout the lifespan. The protein undergoes proteolytic processing to release its intracellular domain (NICD2), which translocates to the nucleus to regulate gene expression programs governing cell fate, survival, and function [1](https://pubmed.ncbi.nlm.nih.gov/12455676/).
Dysregulation of Notch2 signaling has been implicated in the pathogenesis of multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers) (AD), [Parkinson's disease](/diseases/parkinsons-disease), and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). The protein's unique expression patterns in neural stem cells, neurons, oligodendrocytes, and vascular smooth muscle cells position it at the intersection of multiple disease-relevant processes [2](https://pubmed.ncbi.nlm.nih.gov/20305642/).
Notch2 is a large type I transmembrane protein with a complex domain architecture that enables its role as a signal transduction molecule. The full-length precursor protein (~300 kDa) undergoes furin-mediated cleavage in the Golgi apparatus to generate a heterodimeric receptor that is subsequently trafficked to the cell surface [3](https://pubmed.ncbi.nlm.nih.gov/14555886/).
The extracellular domain of Notch2 (approximately 210 kDa) contains 36 epidermal growth factor-like (EGF) repeats followed by three LIN-12/Notch repeats (LNR). The EGF-like repeats are critical for ligand binding and determine binding specificity for Notch ligands (Jagged1, Jagged2, Delta-like 1, Delta-like 3, Delta-like 4). Each EGF repeat contains conserved cysteine residues that form disulfide bonds, stabilizing the domain structure [4](https://pubmed.ncbi.nlm.nih.gov/12055623/).
The LNR domain sits immediately adjacent to the transmembrane domain and functions as an autoinhibitory module. In the absence of ligand binding, the LNR domain prevents receptor activation by maintaining the receptor in a closed conformation. This conformational locking is essential for preventing spurious signaling, as ligand binding must overcome this inhibition to trigger receptor activation.
The transmembrane domain consists of a single α-helix that spans the plasma membrane. This domain contains the site of γ-secretase cleavage—a pivotal event in Notch signal transduction. Following ADAM-mediated shedding of the extracellular domain, the remaining membrane-tethered fragment undergoes a conformational change that exposes the γ-secretase cleavage site [5](https://pubmed.ncbi.nlm.nih.gov/11940529/).
The intracellular domain of Notch2 (NICD2, ~110 kDa) contains several functional modules that drive transcriptional activation. The N-terminal RAM domain provides high-affinity binding to CSL transcription factors (CBF1/RBP-Jκ/Su(H)/LAG-1). Adjacent to the RAM domain are six ankyrin (ANK) repeats that form the core transcriptional activation complex [6](https://pubmed.ncbi.nlm.nih.gov/11229402/).
The ankyrin repeats are flanked by two transcriptional activation domains (TAD1 and TAD2) that are unique to Notch family members and critical for transcriptional activation. At the C-terminus, a PEST (proline-glutamate-serine-threonine) domain regulates protein stability through phosphorylation-dependent ubiquitin-mediated degradation. The overall half-life of NICD2 is approximately 2-4 hours, allowing for rapid signal termination [7](https://pubmed.ncbi.nlm.nih.gov/11018038/).
The canonical Notch2 signaling pathway operates through a mechanism of regulated intramembranous proteolysis (RIP). Signal transduction is initiated when the Notch2 extracellular domain on a signal-receiving cell engages with a Notch ligand (Jagged or Delta-like) expressed on an adjacent signal-sending cell [8](https://pubmed.ncbi.nlm.nih.gov/17652093/).
This cell-cell interaction triggers a conformational change that exposes the ADAM cleavage site. ADAM10 or ADAM17 catalyzes the first proteolytic cleavage (S1), releasing the majority of the extracellular domain. The remaining membrane-tethered fragment (Notch2ΔE) undergoes a second cleavage (S2) that is mediated by γ-secretase, releasing the Notch2 intracellular domain (NICD2) into the cytoplasm [9](https://pubmed.ncbi.nlm.nih.gov/17148752/).
NICD2 then translocates to the nucleus, where it associates with the CSL transcription factor complex. The binding of NICD2 displaces transcriptional repressors (co-repressors such as NCoR, SMRT, and HDAC) and recruits co-activators including Mastermind-like proteins (MAML1-4). This assembled complex drives transcription of downstream target genes, most notably the HES (Hairy and Enhancer of Split) and HEY (Hairy/Enhancer-of-Split related with YRPW motif) families of basic helix-loop-helix transcription factors [10](https://pubmed.ncbi.nlm.nih.gov/11430817/).
Beyond canonical signaling, Notch2 can participate in several non-canonical signaling mechanisms that expand its functional repertoire. These alternative pathways include:
Ligand-Independent Activation: Notch2 can be activated in the absence of ligand through mechanisms involving ADAM-mediated shedding followed by γ-secretase cleavage. This can be triggered by cellular stresses, hypoxia, or accumulation of reactive oxygen species [11](https://pubmed.ncbi.nlm.nih.gov/19056846/).
CSL-Independent Signaling: NICD2 can function without CSL through direct interaction with other transcription factors and signaling proteins. Examples include interactions with NF-κB, PI3K/Akt signaling, and β-catenin [12](https://pubmed.ncbi.nlm.nih.gov/19081067/).
Cross-talk with Other Pathways: Notch2 extensively cross-talks with numerous signaling pathways including Wnt/β-catenin, Hedgehog, TGF-β, and RTK signaling pathways. These interactions allow Notch2 to integrate signals from diverse cellular contexts and modulate cellular responses accordingly.
In the developing and adult central nervous system, Notch2 is highly expressed in neural stem cells (NSCs) and neural progenitor cells (NPCs). In the adult brain, NSCs in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the hippocampal dentate gyrus express Notch2 at high levels [13](https://pubmed.ncbi.nlm.nih.gov/15689561/).
Notch2 signaling in NSCs promotes maintenance of the undifferentiated state and inhibits premature neuronal differentiation. This function is mediated through HES1 and HES5, which repress pro-neural transcription factors including Mash1, NeuroD1, and Ngn1/2. The balance between Notch2 signaling and pro-neural transcription factor activity determines whether NSCs remain proliferative or undergo differentiation [14](https://pubmed.ncbi.nlm.nih.gov/11577321/).
While Notch2 expression decreases as neurons mature, significant levels persist in many neuronal populations in the adult brain. Immunohistochemical studies have demonstrated Notch2 localization in neuronal cell bodies and dendritic processes throughout the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus) [15](https://pubmed.ncbi.nlm.nih.gov/20305642/).
At synapses, Notch2 co-localizes with presynaptic markers and postsynaptic density proteins including PSD-95. Functional studies have demonstrated that Notch2 modulates synaptic transmission and plasticity, influencing both glutamatergic and GABAergic signaling. Knockdown of Notch2 in hippocampal neurons reduces dendritic spine density and impairs long-term potentiation (LTP) [16](https://pubmed.ncbi.nlm.nih.gov/20668448/).
Notch2 expression extends to multiple glial cell populations. Oligodendrocyte precursor cells (OPCs) express Notch2, which promotes proliferation while inhibiting differentiation—a state that must be overcome for successful remyelination [17](https://pubmed.ncbi.nlm.nih.gov/18558512/). Astrocytes also express Notch2, with increased expression observed in reactive astrocytes surrounding lesions in multiple sclerosis and other neuroinflammatory conditions.
In the cerebrovascular system, Notch2 is expressed in vascular smooth muscle cells and pericytes, where it plays essential roles in vessel development and maintenance. Notch2 (along with Notch3) regulates expression of genes involved in smooth muscle cell contractility, extracellular matrix production, and blood pressure regulation [18](https://pubmed.ncbi.nlm.nih.gov/26255967/).
Notch2 has emerged as a player in Alzheimer's disease pathogenesis through multiple mechanisms. The protein shares structural homology with [amyloid precursor protein](/entities/app-protein) (APP), and both are substrates for the same secretase enzymes (ADAM10/ADAM17 and γ-secretase) [19](https://pubmed.ncbi.nlm.nih.gov/17658244/).
In Alzheimer's disease brains, Notch2 expression is altered in vulnerable neuronal populations. Studies have reported both increased and decreased Notch2 expression depending on brain region and disease stage, suggesting complex dysregulation rather than simple up- or down-regulation. The presence of amyloid-beta plaques appears to influence Notch2 signaling through several mechanisms:
Competition for γ-Secretase: Notch2 and APP compete for γ-secretase cleavage, creating potential interactions with amyloid-beta production. Some studies suggest that increased Notch2 signaling can reduce amyloid-beta generation through substrate competition, though this effect may be context-dependent [20](https://pubmed.ncbi.nlm.nih.gov/17148752/).
Neuroprotective Signaling: Activation of Notch2 can protect neurons against amyloid-beta toxicity through upregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL) and activation of pro-survival pathways including PI3K/Akt and NF-κB [21](https://pubmed.ncbi.nlm.nih.gov/19443799/).
Effects on Synaptic Plasticity: Notch2 modulates synaptic function and plasticity, processes that are impaired in AD. Notch2 signaling influences NMDA receptor function, dendritic spine morphology, and memory consolidation—all of which are compromised in Alzheimer's disease [22](https://pubmed.ncbi.nlm.nih.gov/20668448/).
Evidence for Notch2 involvement in Parkinson's disease (PD) is emerging, though less extensive than for AD. Post-mortem studies have detected altered Notch2 expression in the substantia nigra of PD brains, with some reports of increased Notch2 in dopaminergic neurons [23](https://pubmed.ncbi.nlm.nih.gov/23698256/).
Notch2 may interact with alpha-synuclein pathology, the hallmark protein aggregation in PD. In cellular models, Notch2 cleavage and signaling can be influenced by alpha-synuclein expression, though the functional consequences remain incompletely understood. Additionally, Notch2 signaling may influence neuroinflammation in PD through effects on microglial activation and inflammatory cytokine production.
Mutations in NOTCH2 cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary small vessel disease leading to stroke and vascular dementia. Over 200 disease-causing mutations have been identified, predominantly in the extracellular domain [24](https://pubmed.ncbi.nlm.nih.gov/15525655/).
These mutations cause misfolding and retention of Notch2 in the endoplasmic reticulum, reducing cell surface expression and creating haploinsufficiency. Vascular smooth muscle cells are particularly affected, leading to the characteristic pathological features of CADASIL including smooth muscle cell degeneration, basement membrane thickening, and accumulation of granular osmiotic material in the vessel wall.
Notch2 has been implicated in demyelinating diseases including multiple sclerosis. In active MS lesions, Notch2 expression is elevated in reactive astrocytes and oligodendrocyte precursors within demyelinated areas [25](https://pubmed.ncbi.nlm.nih.gov/19081067/). The functional significance of this upregulation remains under investigation, but Notch2 signaling in OPCs may contribute to failed remyelination by maintaining cells in a proliferative, undifferentiated state.
The therapeutic targeting of Notch2 presents both opportunities and challenges. The pathway's essential roles in development and tissue homeostasis mean that systemic inhibition can cause significant adverse effects. Nevertheless, several strategies are being explored:
Gamma-secretase inhibitors (GSIs) block the cleavage of all Notch receptors, including Notch2. However, these compounds cause severe gastrointestinal toxicity due to Notch1 inhibition in intestinal stem cells, limiting clinical utility [26](https://pubmed.ncbi.nlm.nih.gov/20090848/). Attempts to develop tissue-selective GSIs or combination approaches to mitigate toxicity are ongoing.
Antibodies targeting the Notch2 extracellular domain can block ligand binding and prevent receptor activation. Such antibodies have shown preclinical efficacy in models of CADASIL, where they may reduce the pathological effects of mutant Notch2 [27](https://pubmed.ncbi.nlm.nih.gov/28765326/).
Small molecules targeting specific aspects of Notch2 signaling are under development. These include inhibitors of the Notch2-MAML interaction that disrupt transcriptional activation without affecting receptor cleavage. Additionally, compounds that enhance Notch2 ubiquitination and degradation offer alternative approaches to pathway inhibition [28](https://pubmed.ncbi.nlm.nih.gov/24795426/).
Rather than targeting Notch2 directly, therapeutic strategies may modulate downstream effectors including Hes1, Hey2, and related transcription factors. This approach offers potential for more selective modulation of specific Notch2 functions while sparing other Notch family members.
Notch2 interacts with numerous proteins and signaling pathways relevant to neurodegeneration:
Notch2 is a multifunctional transmembrane receptor with critical roles in neural development, synaptic plasticity, and vascular homeostasis. Its involvement in Alzheimer's disease through interactions with APP processing, neuroprotective signaling, and synaptic modulation highlights its potential as a therapeutic target. In CADASIL, Notch2 mutations directly cause disease, providing a definitive link between Notch2 dysfunction and neurodegeneration. Continued investigation of Notch2 biology and its contributions to disease pathogenesis will be essential for developing effective neuroprotective strategies targeting this important signaling molecule.